atrial fibrillation
Conditions
Interventions
intervention group:The total course of treatment for Shensong Yangxin Capsules 1.6g tid+Dronedarone 400mg bid orally was 3 months, and later changed to Shensong Yangxin Capsules 1.6g tid to maintain f
control group:Dronedarone 400mg bid for a total course of 3 months
Sponsors
Mianyang 404 Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with persistent atrial fibrillation aged >= 18 years and <= 85 years old; 2. NYHA functional class I-III; 3. Perform radiofrequency ablation for atrial fibrillation. 4. Obtain informed consent from the patient and complete a 1-year follow-up.
Exclusion criteria
Exclusion criteria: 1. Unable to complete the expected 1-year follow-up; 2. Serious hematological disorders with contraindications to anticoagulation; 3. Left atrial diameter >= 65mm; 4. Left atrial appendage thrombus (transesophageal ultrasound examination); 5. NYHA functional class IV; 6. Hyperthyroidism or hypothyroidism; 7. Severe liver and kidney dysfunction; 8. Expected survival time<1 year; 9. Other arrhythmias/malignant arrhythmias
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year recurrence rate of atrial fibrillation after radiofrequency ablation;complication; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of quality of life;Decreased heart rate; | — |
Countries
China
Contacts
Public ContactZhou Tao
Mianyang 404 Hospital
Outcome results
None listed